دورية أكاديمية
Relationship between CD44 high /CD133 high /CD117 high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines.
| العنوان: | Relationship between CD44 high /CD133 high /CD117 high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines. |
|---|---|
| المؤلفون: | Silva Galbiatti-Dias AL; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil., Fernandes GMM; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil., Castanhole-Nunes MMU; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil., Hidalgo LF; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil., Nascimento Filho CHV; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil., Kawasaki-Oyama RS; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil., Ferreira LAM; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil., Biselli-Chicote PM; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil., Pavarino ÉC; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil., Goloni-Bertollo EM; Genetics and Molecular Biology Research Unit (UPGEM), São José do Rio Preto Medical School (FAMERP) SP, Brazil. |
| المصدر: | American journal of cancer research [Am J Cancer Res] 2018 Aug 01; Vol. 8 (8), pp. 1633-1641. Date of Electronic Publication: 2018 Aug 01 (Print Publication: 2018). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: e-Century Pub. Corp Country of Publication: United States NLM ID: 101549944 Publication Model: eCollection Cited Medium: Print ISSN: 2156-6976 (Print) Linking ISSN: 21566976 NLM ISO Abbreviation: Am J Cancer Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Madison, WI : e-Century Pub. Corp., [2011]- |
| مستخلص: | Recent evidence suggests that cancer stem cells (CSCs), a small population of cancer cells that are highly tumourigenic, capable of self-renewal and have the ability to differentiate into cells that constitute the tumor, are the "drivers" of local recurrence and metastatic spread and may be associated with resistant to conventional therapy. The objectives of the study are to identify and characterize two head and neck cancer cell lines with regard CD44 high /CD133 high /CD117 high profile (CSCs) and CD44 low /CD133 low /CD117 low profile (Non-CSCs); to investigate the influence of chemotherapy treatment in CSCs and compare with Non-CSCs; to evaluate CD44 and EGFR gene expression in CSCs. Fluorescent-activated cell sorting (FACS) using specific cell surface marker combination (CD44, CD117 and CD133) was performed to isolate CSCs of Non-CSCs from cell lines. The Wound Healing assay was performed to confirm the presence of CSCs. After, the CSCs subpopulation and Non-CSCs were cultured and exposed for 24 h to Cetuximab and Paclitaxel treatment, separately. Cell proliferation was determined by MTS assay. CD44 and EGFR gene expression was quantified by quantitative real time PCR (qPCR) using TaqMan ® Assay in both subpopulations. CSCs subpopulation untreated were considered as relative expression control. We firstly characterized CSCs in HN13 and HEP-2 cell lines with CD44, CD133 and CD117 biomarkers. We treated CSCs and Non-CSCs subpopulations with Cetuximab and Paclitaxel treatment and found that CSCs subpopulations demonstrated more resistance to Paclitaxel chemoterapy, when compared with Non-CSCs subpopulations of oral cancer cell line. These CSCs subpopulations presented up-regulation of CD44 gene and down-regulation of EGFR gene in oral cancer cell line, and down-regulation of CD44 gene and up-regulation of EGFR gene in laryngeal cancer cell line when compared with Non-CSCs subpopulations. We conclude that the combination of CD44, CD133 and CD117 biomarkers have stem cell properties in both cell lines. CSCs has ability to resist to Paclitaxel treatment in oral cancer cell line. CSCs present high expression of CD44 gene and down expression of EGFR gene in oral cancer cell line. CSCs in laryngeal cell line present down expression of CD44 gene and high expression of EGFR gene when compared with cells without characteristics of cancer stem cells. Competing Interests: None. |
| References: | J Cancer Res Ther. 2018 Jan;14(1):1-5. (PMID: 29516950) Oncotarget. 2014 Aug 30;5(16):6620-32. (PMID: 25216514) Annu Rev Med. 2007;58:267-84. (PMID: 17002552) Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Mar;28(6):400-5. (PMID: 24961129) Oral Oncol. 2009 Jul;45(7):633-9. (PMID: 19027347) Cancers (Basel). 2016 Feb 26;8(3):. (PMID: 26927178) Cell Mol Biol (Noisy-le-grand). 2015 Oct 30;61(6):39-43. (PMID: 26518895) Rom J Morphol Embryol. 2011;52(3 Suppl):985-93. (PMID: 22119814) Cell Prolif. 2009 Aug;42(4):434-47. (PMID: 19486015) Cancer Res. 2005 Oct 1;65(19):8944-50. (PMID: 16204067) Nature. 2006 Dec 7;444(7120):756-60. (PMID: 17051156) Int J Radiat Biol. 2014 Aug;90(8):622-7. (PMID: 24460132) World J Clin Oncol. 2016 Apr 10;7(2):220-6. (PMID: 27081644) World J Stem Cells. 2016 Jan 26;8(1):13-21. (PMID: 26839637) Pharmacogenomics. 2018 Jun 1;19(8):727-740. (PMID: 29785875) Biochim Biophys Acta. 2016 Dec;1866(2):276-289. (PMID: 27751894) J Clin Oncol. 2010 Mar 1;28(7):1254-61. (PMID: 20100961) PLoS One. 2012;7(9):e44071. (PMID: 23049743) Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. (PMID: 19805294) Front Oncol. 2017 Jun 02;7:112. (PMID: 28626726) J Oral Pathol Med. 2013 Oct;42(9):682-90. (PMID: 23627635) Cancer Res. 2011 Aug 1;71(15):5317-26. (PMID: 21685475) Braz J Otorhinolaryngol. 2013 Mar-Apr;79(2):239-47. (PMID: 23670332) Int J Clin Exp Med. 2014 Sep 15;7(9):2453-62. (PMID: 25356097) Oncotarget. 2014 Mar 30;5(6):1491-501. (PMID: 24721839) Cancer J. 2017 Mar/Apr;23(2):79-83. (PMID: 28410291) Radiother Oncol. 2011 Oct;101(1):158-64. (PMID: 21665310) Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8. (PMID: 17210912) Cancer Sci. 2016 Jul;107(7):875-81. (PMID: 27116333) Clin Pharmacol Ther. 2011 Apr;89(4):491-502. (PMID: 21368752) Cancer Res. 2017 Mar 1;77(5):1188-1199. (PMID: 28031227) Oncol Rep. 2018 Apr;39(4):1783-1792. (PMID: 29393480) Adv Biol Regul. 2014 Sep;56:45-50. (PMID: 24925031) Oral Oncol. 2015 Jul;51(7):643-51. (PMID: 25920765) Clin Otolaryngol. 2015 Aug;40(4):312-20. (PMID: 25641707) Cancer Treat Rev. 2016 Mar;44:10-6. (PMID: 26924194) Lung Cancer. 2018 Feb;116:80-89. (PMID: 29413056) BMC Cancer. 2014 Mar 11;14:173. (PMID: 24612587) J Cancer Res Ther. 2018 Jan-Mar;14(2):245-248. (PMID: 29516902) J Biomed Res. 2013 Sep;27(5):394-405. (PMID: 24086173) J Thorac Oncol. 2015 Jul;10(7):1027-36. (PMID: 26020124) Cancer Lett. 2010 Mar 28;289(2):151-60. (PMID: 19748175) Biomed Res Int. 2013;2013:517237. (PMID: 24294611) Biomed Res Int. 2017;2017:7407168. (PMID: 28573141) Cancers (Basel). 2016 Jan 04;8(1):. (PMID: 26742076) Oncogene. 2012 May 17;31(20):2521-34. (PMID: 21963846) Head Neck. 2016 Apr;38 Suppl 1:E231-8. (PMID: 25545959) Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):771-8. (PMID: 16847188) Nat Med. 2012 Feb 06;18(2):199-200. (PMID: 22310681) |
| فهرسة مساهمة: | Keywords: CD44; Cancer stem cells; EGFR; cell line; chemotherapy; expression; gene; head and neck neoplasias |
| تواريخ الأحداث: | Date Created: 20180914 Latest Revision: 20240330 |
| رمز التحديث: | 20240330 |
| مُعرف محوري في PubMed: | PMC6129494 |
| PMID: | 30210931 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2156-6976 |
|---|